SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with previously treated neovascular age-related macular degeneration

Clare Bailey,¹ Clemens Lange,^{2,3} Varun Chaudhary,⁴ Paolo Lanzetta,^{5,6} Hassiba Oubraham,⁷ Martin Kirchner,⁸ Tobias Machewitz,⁹ Helmut Allmeier,¹⁰ Xin Zhang,¹⁰ Zoran Hasanbasic,¹⁰ Marion R. Munk,^{11,12,13} on behalf of the SPECTRUM study investigators

¹Department of Ophthalmology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK; ²Eye Center, Faculty of Medicine, Albert-Ludwig University Freiburg, Freiburg, Germany; ³Department of Ophthalmology, St. Franziskus Hospital, Münster, Germany; ⁴Hamilton Regional Eye Institute, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada; ⁵Department of Medicine–Ophthalmology, University of Udine, Udine, Italy; ⁶Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, Milan, Italy; ⁷Centre OPHTA-45, Montargis, France; ⁸Bayer AG, Leverkusen, Germany; ⁹Bayer AG, Berlin, Germany; ¹⁰Bayer Consumer Care AG, Basel, Switzerland; ¹¹Augenarzt Praxisgemeinschaft Gutblick AG, Pfäffikon, Switzerland; ¹²Department of Ophthalmology, University Hospital Bern, Bern, Switzerland; ¹³Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.



- Regulatory approval of the aflibercept 8 mg formulation in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)^{1,2} was based on the PULSAR (Phase 3),³ PHOTON (Phase 2/3)⁴ and CANDELA (Phase 2)⁵ clinical trials
- SPECTRUM is the first global Phase 4 study to collect real-world data on the effectiveness and safety of aflibercept 8 mg in the treatment of nAMD and DME
- Here, we present early clinical outcomes at Week 8 in patients with previously treated nAMD from the SPECTRUM trial



- Early clinical experience indicates stable visual acuity (VA) and reductions in central retinal thickness (CRT; -39 µm) at Week 8 in patients with previously treated nAMD in realworld settings
- To date, **no new safety signals have been reported** for aflibercept 8 mg in this cohort
- Early insights from the SPECTRUM study will help inform **clinical management** of previously treated nAMD in patients receiving aflibercept 8 mg

Acknowledgments

The SPECTRUM study was sponsored by Bayer Consumer Care AG (Basel, Switzerland). The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this poster. Medical writing support, under the direction of the authors, was provided by ApotheCom and funded by Bayer Consumer Care AG, Basel, Switzerland, in accordance with Good Publication Practice (GPP) guidelines (Ann Intern Med. 2022;175:1298–1304).

References

- 1. Eylea. European Medicines Agency. 2025.
- 2. Drugs@FDA: FDA-Approved Drugs. U.S. Food and Drug Administration. 2023.
- 3. Lanzetta P, et al. Lancet. 2024;403:1141–1152
- 4. Brown DM, et al. Lancet. 2024;403:1153-1163. 5. Wykoff CC, et al. JAMA Ophthalmol. 2023;141:834–842.



76203085-44 BAYER RWC poster SPECTRUM nAMD PT 36x48 inches V01.indo

Scan the QR code to access the **RWC 2025** planner and abstracts


Presented at the 2025 **Retina World Congress**, Fort Lauderdale, FL, USA, May 8–11, 2025

Methods

Results

- overall baseline of 316 µm (**Figure 3**)

- Total: 104 patients
- Mean age: 79.5 ± 7.3 years



Disclosures

Clare Bailey: Honoraria: Alimera Sciences, Apellis, Bayer, and Roche; advisory boards: Apellis, Bayer, Boehringer Ingelheim, Janssen, and Roche; CL: Honoraria: Apellis, Bayer, Biogen, and Novartis; VC: Consulting fees: EyePoint; grants: Bayer, Novartis, Roche; advisory boards: Alcon, Apellis, Bayer, Boehringer Ingelheim, Novartis, and Roche; PL: Consultant: Aerie Pharmaceuticals, Allergan, Annexon, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, EyePoint Pharmaceuticals, Genentech, I-Care, Novartis, Ocular Therapeutics, and Roche; HO: Consultant: AbbVie, Bayer, Novartis, and Roche; MK and TM: Employees: Bayer AG; HA, XZ and ZH: Employees: Bayer Consumer Care AG; MRM: Consulting fees: AbbVie, Allergan, Apellis, Aviceda Therapeutics, Bayer, Boehringer Ingelheim, Dandelion, Eyepoint, Gensight, Iveric Bio, Isarna Therapeutics, Kubota, Lumithera, Novartis, Ocuterra, Oculis, Ocular Therapeutix, RetinAI, Roche, and Zeiss.